NEPTUNE: Phase 3 Study of First-Line Durvalumab Plus Tremelimumab in Patients With Metastatic NSCLC-Reference-Cited by-同舟云学术

NEPTUNE: Phase 3 Study of First-Line Durvalumab Plus Tremelimumab in Patients With Metastatic NSCLC

Published:2023-01 Issue:1 Volume:18 Page:106-119
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

de Castro Gilberto,Rizvi Naiyer A.,Schmid Peter,Syrigos Konstantinos,Martin Claudio,Yamamoto Nobuyuki,Cheng Ying,Moiseyenko Vladimir,Summers Yvonne,Vynnychenko Ihor,Lee Sung Yong,Bryl Maciej,Zer Alona,Erman Mustafa,Timcheva Constanta,Raja Rajiv,Naicker Kirsha,Scheuring Urban,Walker Jill,Mann Helen,Chand Vikram,Mok Tony

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference30 articles.

1. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial;Mok;Lancet,2019

2. Pembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer;Gandhi;N Engl J Med,2018

3. Pembrolizumab plus chemotherapy for squamous non–small-cell lung cancer;Paz-Ares;N Engl J Med,2018

4. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC;Socinski;N Engl J Med,2018

5. Durvalumab with or without tremelimumab vs standard chemotherapy in first-line treatment of metastatic non-small-cell lung cancer: the MYSTIC phase 3 randomized clinical trial;Rizvi;JAMA Oncol,2020

Cited by 35 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Overcoming Cancer Resistance: Strategies and Modalities for Effective Treatment;Biomedicines;2024-08-08

2. First-line immune checkpoint inhibitors in low programmed death-ligand 1-expressing population;Frontiers in Pharmacology;2024-07-26

3. Novel Combinations of Immunotherapies or DNA Damage Repair Inhibitors in Platinum-Refractory Extensive-Stage Small Cell Lung Cancer: The Phase II BALTIC Study;Clinical Cancer Research;2024-07-17

4. Blood Tumor Mutational Burden Alone Is Not a Good Predictive Biomarker for Response to Immune Checkpoint Inhibitors in Patients With Gastrointestinal Tumors;Journal of Immunotherapy;2024-07-16

5. The role of immunotherapy in early-stage and metastatic NSCLC;Pathology and Oncology Research;2024-07-04